Binds Enzyme Patents (Class 530/388.26)
-
Patent number: 6887705Abstract: This invention concerns new PSTPIP polypeptides which are bound by and dephosphorylated by the PEST family of protein tyrosine phosphatases. The invention specifically concerns native murine PSTPIP polypeptides and their homologues in other mammals, and their functional derivatives. The invention further relates to nucleic acids encoding these proteins, vectors containing and capable of expressing such nucleic acid, and recombinant host cells transformed with such nucleic acid. Methods for inducing the plymerization of actin monomers in eukaryotic cells and assays for identifying antagonists and agonists of the PSTPIP polypeptides of the present invention are also provided.Type: GrantFiled: January 30, 1998Date of Patent: May 3, 2005Assignee: Genentech, Inc.Inventors: Laurence A. Lasky, Donald J. Dowbenko
-
Patent number: 6884872Abstract: The present invention provides polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins. In particular, the polypeptides and polynucleotides of the invention comprise amino acid and nucleic acid sequences of novel CD39-like gene and gene products.Type: GrantFiled: July 13, 2001Date of Patent: April 26, 2005Assignee: NUVELO, Inc.Inventors: Brian Paul Chadwick, Anna-Maria Frischauf
-
Patent number: 6878810Abstract: Angiotensin-converting enzyme is a zinc metallopeptidase that plays roles in blood pressure regulation and fertility. The catalytic activities of angiotensin converting enzymes include the production of the potent vasopressor angiotensin II from angiotensin I, and the inactivation of the vasodilatory peptide bradykinin. Zace1 is a new form of human zinc metallopeptidase, which includes one zinc-dependent catalytic domain containing the motif “HEXXH” and one downstream “EX(I/V)X(D/S)” motif.Type: GrantFiled: September 17, 2002Date of Patent: April 12, 2005Assignee: ZymoGenetics, Inc.Inventor: Paul O. Sheppard
-
Patent number: 6878812Abstract: The present invention relates to novel metalloproteinase-like proteins. In particular, isolated nucleic acid molecules are provided encoding the human TACE-like and matrilysin-like proteins. TACE-like and matrilysin-like polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TACE-like and matrilysin-like activity. Also provided are diagnostic methods for detecting cancer and therapeutic methods for cancer and other disorders characterized by an over or under production of these metalloproteinases.Type: GrantFiled: September 13, 2001Date of Patent: April 12, 2005Assignee: Human Genome Science, Inc.Inventors: Jian Ni, Steve Ruben, Laurie Brewer, Reiner Gentz, Craig Rosen
-
Patent number: 6849450Abstract: A novel metalloproteinase inhibitor, analogs thereof, polynucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders caused by excessive amounts of metalloproteinase are also disclosed.Type: GrantFiled: February 21, 1997Date of Patent: February 1, 2005Assignees: Childrens Hospital of Los Angeles, Amgen Inc.Inventors: Keith E. Langley, Yves A. DeClerck, Thomas C. Boone
-
Publication number: 20040265968Abstract: The present invention relates to a novel t-PALP protein which is a member of the serine protease family. In particular, isolated nucleic acid molecules are provided encoding the human t-PALP protein. t-PALP polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of t-PALP activity. Also provided are diagnostic methods for detecting circulatory system-related disorders and therapeutic methods for treating circulatory system-related disorders.Type: ApplicationFiled: July 20, 2004Publication date: December 30, 2004Applicant: Human Genome Sciences, Inc.Inventors: Paul A. Moore, Steven M. Ruben, Reinhard Ebner
-
Publication number: 20040265310Abstract: A novel gene (designated 30P3C8) and its encoded protein is described. 30P3C8 exhibits restricted tissue expression in normal adult tissue and is overexpressed in prostate tissue xenografts, providing evidence that it is aberrantly expressed in at least some prostate cancers. Consequently, 30P3C8 provides a diagnostic and/or therapeutic target for prostate cancers.Type: ApplicationFiled: January 16, 2004Publication date: December 30, 2004Inventors: Daniel E. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran
-
Publication number: 20040265891Abstract: The invention provides a polypeptide which encodes human presenilin variant. It also provides for the use of the cDNA and protein in the diagnosis, prognosis, treatment and evaluation of therapies for cancer or neurodegenerative or immune disorders. The invention further provides vectors and host cells for the production of the protein and transgenic model systems.Type: ApplicationFiled: July 12, 2004Publication date: December 30, 2004Applicant: Incyte Genomics, Inc.Inventors: Chandra Arvizu, Lynn E. Murry, Matthew R. Kaser
-
Publication number: 20040265849Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with Alzheimer's disease. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: ApplicationFiled: November 24, 2003Publication date: December 30, 2004Applicant: APPLERA CORPORATIONInventors: Michele Cargill, Andrew Grupe, Yonghong Li
-
Publication number: 20040258682Abstract: A humanized specific monoclonal antibody or antibody fragment, especially a B-cell specific antibody or antibody fragment, is engineered to contain a glycosylation site in the non-Fc constant region. The glycosylated antibody is useful for diagnosis and/or therapy whenever a targeting antibody or fragment is used, especially for B-cell malignancies. The carbohydrate moiety allows conjugation of labeling or therapeutic agents of increased size, without affecting the binding affinity or specificity of the antibody.Type: ApplicationFiled: February 27, 2004Publication date: December 23, 2004Applicant: Immunomedics, IncInventors: Shui-on Leung, Hans J. Hansen, Zhengxing Qu
-
Publication number: 20040259163Abstract: The present invention relates to polynucleotide and polypeptide molecules, and variants thereof, for MAPP, a novel member of the Disintegrin Proteases. The polypeptides, and polynucleotides encoding them, are cell-cell interaction modulating and may be used for delivery and therapeutics. The present invention also includes antibodies to the MAPP polypeptides.Type: ApplicationFiled: May 25, 2004Publication date: December 23, 2004Applicant: ZymoGenetics, Inc.Inventors: Paul O. Sheppard, Nand Baindur, Paul D. Bishop
-
Publication number: 20040259198Abstract: MAT II &bgr; subunit proteins and cDNAs encoding the same. Recombinant host cells, recombinant nucleic acids and recombinant proteins are also disclosed, along with methods of producing each. Isolated and purified antibodies to MAT II &bgr; subunit homologs, and methods of producing the same, are also disclosed. MAT II &bgr; subunit gene products are characterized as having activity in modulating the biological activity of MAT II. Thus, therapeutic methods involving these activities are also disclosed.Type: ApplicationFiled: February 20, 2004Publication date: December 23, 2004Inventors: Malak Kotb, H. Leighton LeGros, Arthur M. Geller
-
Publication number: 20040259207Abstract: DNAs encoding canine Cathepsin S have been cloned and characterized. The recombinant protein is capable of forming biologically active protein. The cDNA's have been expressed in recombinant host cells that produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.Type: ApplicationFiled: July 19, 2004Publication date: December 23, 2004Inventors: Robin Thurmond, Lars Karlsson, Sherry Baker
-
Publication number: 20040259206Abstract: DNAs encoding monkey cathepsin S have been cloned and characterized. The recombinant protein is capable of forming biologically active protein. The cDNA's have been expressed in recombinant host cells that produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.Type: ApplicationFiled: July 19, 2004Publication date: December 23, 2004Inventors: Robin Thurmond, Lars Karlsson, Sherry Baker
-
Publication number: 20040253683Abstract: Vaccines, antibodies, proteins, DNAs and RNAs for diagnosis, prophylaxis, treatment and detection of Cryptosporidium species or Cryptosporidium species infections. Cryptosporidium species antigen and DNAs and RNA encoding the Cryptosporidium antigen and fragments thereof and recombinant proteins or fusion proteins produced thereby. Methods for diagnosis, prophylaxis, treatment and detection of Cryptosporidium species infections.Type: ApplicationFiled: June 14, 2004Publication date: December 16, 2004Inventors: Carolyn Petersen, Jin-Xing Huang
-
Publication number: 20040253221Abstract: A novel phospholipase A1 (PLA1) having a substrate specificity for phosphatidic acid (PA): a peptide or a polypeptide originating in the novel PLA1: a polynucleotide encoding the peptide or the polypeptide originating in the novel PLA1: a process for producing the peptide or the polypeptide originating in the novel PLA1: an antibody against the peptide or the polypeptide originating in the novel PLA1: a method of identifying an inhibitor, an antagonist or a potentiator for the novel PLA1 by using the same: a compound identified by this method: and medicinal compositions and a diagnostic method with the use of the same.Type: ApplicationFiled: August 18, 2003Publication date: December 16, 2004Inventors: Hiroyuki Arai, Junken Aoki
-
Publication number: 20040253701Abstract: This invention provides for murine telomerase reverse transcriptase (mTERT) enzyme proteins and nucleic acids, including methods for isolating and expressing these nucleic acids and proteins, which have application to the control of cell proliferation and aging, including the control of age-related diseases, such as cancer.Type: ApplicationFiled: June 7, 2004Publication date: December 16, 2004Inventors: Gregg B. Morin, Richard Allsopp, Ronald A. De Pinho, Roger A. Greenberg
-
Publication number: 20040247600Abstract: Compositions and methods involving agents that specifically bind to methylthioadenosine phosphorylase (MTAP) protein are disclosed. Illustrative compositions comprise binding agents that bind to human MTAP protein in biological samples, including embedded samples. The binding agents are useful, for example, in the detection, prognosis, and/or treatment of MTAP deficient cancers. Also disclosed are kits containing the reagents necessary for the detection of human MTAP protein in an embedded sample.Type: ApplicationFiled: February 13, 2004Publication date: December 9, 2004Inventor: Lorenzo M. Leoni
-
Publication number: 20040248244Abstract: The invention provides an isolated nucleic acid molecule having substantially the same nucleotide sequence as SEQ ID NO:1. Also provided is an isolated oligonucleotide having at least 15 contiguous nucleotides of a nucleotide sequence referenced as SEQ ID NO:11. An isolated polypeptide having substantially the same amino acid sequence as SEQ ID NO:2 is further provided as well as an antibody, or antigen binding fragment thereof, which specifically binds to an ATX polypeptide and has an amino acid sequence as referenced in SEQ ID NO:2. A method for identifying an ATX-modulatory compound is additionally provided. The method consists of measuring the level of an ATX polypeptide in the presence of a test compound, wherein a difference in the level of said ATX polypeptide in the presence of said test compound compared to in the absence of said test compound indicating that said test compound is an ATX-modulatory compound, and wherein said ATX-modulatory compound is not caffeine or wortmannin.Type: ApplicationFiled: June 6, 2003Publication date: December 9, 2004Inventors: Robert T. Abraham, Diane M. Otterness
-
Publication number: 20040248274Abstract: The invention relates to isolated polypeptides having &agr;-H-&agr;-amino acid amide racemase activity and nucleic acids encoding the same. The invention also relates to vectors and host cells comprising the nucleic acids according to the invention. The invention also relates to methods of producing and using the polypeptides according to the invention. The invention also relates to a method for isolating polypeptides having &agr;-H-&agr;-amino acid amide racemase activity, for isolating nucleic acids encoding the same and for isolating microorganisms comprising polypeptides having &agr;-H-&agr;-amino acid amide racemase activity. The invention also relates to new microorganisms comprising polypeptides having &agr;-H-&agr;-amino acid amide racemase activity.Type: ApplicationFiled: December 9, 2003Publication date: December 9, 2004Inventors: Wilhelmus Hubertus Joseph Boesten, Petronella Catharina Raemakers-Franken, Theodorus Sonke, Gerrit Jan Willem Euverink, Pieter Grijpstra
-
Publication number: 20040241157Abstract: The present invention relates to methods and compositions for the amelioration of symptoms mediated by the collagenolytic activity of cathepsin K complex. The invention provides methods of specifically modulating the collagenolytic activity of cathepsin K without substantial interference in other biologically-relevant activities of cathepsin K.Type: ApplicationFiled: July 8, 2004Publication date: December 2, 2004Inventor: Dieter Bromme
-
Publication number: 20040241794Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the drug-metabolizing enzyme peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the drug-metabolizing enzyme peptides, and methods of identfying modulators of the drug-metabolizing enzyme peptides.Type: ApplicationFiled: May 4, 2004Publication date: December 2, 2004Inventors: Wei Shao, Gennady V Merkulov, Valentina Di Francesco, Ellen M Beasley
-
Publication number: 20040241745Abstract: Substances comprising a substance that recognizes PD-1, a substance that recognizes a membrane protein co-existing with PD-1 on a cell membrane, and a linker.Type: ApplicationFiled: February 2, 2004Publication date: December 2, 2004Inventors: Tasuku Honjo, Shiro Shibayama, Masayoshi Matsuo, Takao Yoshida
-
Patent number: 6825000Abstract: An immunoassay reagent is obtained whereby a microscale substance such as an antigen or antibody can be assayed at a high sensitivity, and whereby a need to separate a reacted substance, e.g., an immunoreacted substance, from an unreacted substance can be eliminated or such a separation can be simplified. An immunoassay reagent, for use in the quantitative determination of a target antigen or antibody present in a sample, containing an insoluble carrier which carries an enzyme and an antibody or antigen corresponding to the antigen or antibody, an enzyme inhibitor for inhibiting the activity of the enzyme and a substrate with which the enzyme reacts.Type: GrantFiled: October 31, 2000Date of Patent: November 30, 2004Assignee: Sekisui Chemical Co., Ltd.Inventors: Masayuki Yokoi, Takayuki Akamine, Katsumi Yoshikawa
-
Publication number: 20040235112Abstract: Compositions and methods are provided for potentiating the activity of the mitogen-activated protein kinase p38. In particular the mitogen-activated protein kinase kinase MEK6, and variants thereof that stimulate phosphorylation of p38 are provided. Such compounds may be used, for example, for therapy of diseases associated with the p38 cascade and to identify antibodies and other agents that inhibit or activate signal transduction via p38.Type: ApplicationFiled: June 16, 2004Publication date: November 25, 2004Applicant: Signal Pharmaceuticals, Inc.Inventors: Bernd Stein, Maria X. H. Yang
-
Publication number: 20040237126Abstract: Disclosed are two nucleic acid molecules from M. incognita encoding malate dehydrogenase-like (MDH-like) polypeptides. The MDH-like polypeptide sequences are also provided, as are vectors, host cells, and recombinant methods for production of MDH-like nucleotides and polypeptides. The invention further relates to screening methods for identifying inhibitors and/or activators, as well as methods for antibody production.Type: ApplicationFiled: April 6, 2004Publication date: November 25, 2004Applicant: Divergence, Inc., a Delaware corporationInventors: Andrew P. Kloek, Brandy Salmon, Deryck Jeremy Williams
-
Publication number: 20040234977Abstract: A novel alanine transaminase gene (ALT2) is isolated from human tissue. ALT2 specific polynucleotides, polypeptides, and antibodies are described. ALT2 is expressed predominately in liver, kidney, brain, muscle, and adipose tissue. ALT2 can be used to diagnose injury and diseases involving tissues expressing ALT2.Type: ApplicationFiled: November 6, 2003Publication date: November 25, 2004Inventors: Da-Wei Gong, Alan Shuldiner, Rongze Yang
-
Publication number: 20040236080Abstract: Provided is a cell growth inhibitor that can be used for treating diseases based on abnormal cell proliferation, and in particular cancer. The cell growth inhibitor contains an anti-glypican 3 antibody as an active ingredient.Type: ApplicationFiled: June 30, 2004Publication date: November 25, 2004Inventors: Hiroyuki Aburatani, Tetsuo Nakamura, Masayuki Tsuchiya
-
Publication number: 20040235018Abstract: The present invention provides a novel human gene ZNFN3A1 whose expression is markedly elevated in a great majority of HCCs compared to corresponding non-cancerous liver tissues. The gene encodes a protein having a zinc finger domain as well as a SET domain and has been found to form a regulatory complex with RNA helicase and RNA polymerase.Type: ApplicationFiled: February 27, 2004Publication date: November 25, 2004Inventors: Yusuke Nakamura, Yoichi Furukawa
-
Publication number: 20040235057Abstract: Amino acid sequences and corresponding nucleic acid sequence of retinoid metabolizing protein found in human, mouse and zebrafish are described, as well as methods of using same.Type: ApplicationFiled: May 28, 2004Publication date: November 25, 2004Applicant: Queen's University at KingstonInventors: P. Martin Petkovich, Jay A. White, Barbara R. Beckett, Glenville Jones
-
Publication number: 20040236081Abstract: The invention relates to an isolated nucleic acid molecule encoding a caspase-14 polypeptide or functional fragment thereof, a vector that contains the nucleic acid molecule and a host cell that contains the vector. The invention also relates to an isolated gene encoding caspase-14, as well as functional fragments thereof. The gene or nucleic acid molecule can include single or double stranded nucleic acids corresponding to coding or non-coding strands of the caspase-14 nucleotide sequence. Isolated caspase-14 polypeptides or functional fragments thereof are also provided, as are antibodies that specifically bind thereto. In addition, the invention relates to methods of identifying compounds that modulate caspase-14 activity.Type: ApplicationFiled: June 17, 2004Publication date: November 25, 2004Applicant: Thomas Jefferson UniversityInventors: Emad S. Alnemri, Teresa Fernandez-Alnemri
-
Publication number: 20040235104Abstract: The invention provides isolated nucleic acids molecules, designated SEF nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing SEF nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a SEF gene has been introduced or disrupted. The invention still further provides isolated SEF proteins, fusion proteins, antigenic peptides and anti-SEF antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: May 7, 2004Publication date: November 25, 2004Applicant: Millennium Pharmaceuticals, Inc.Inventor: Ruey-Bing Yang
-
Patent number: 6822080Abstract: Substantially pure human cyclin-dependent kinase-like proteins PITALRE and PISSLRE and isolated protein complexes that comprise PITALRE or PISSLRE are disclosed. Isolated nucleic acid molecule that encode PITALRE or PISSLRE, or a fragment thereof; recombinant expression vectors that comprise nucleic acid sequence that encode PITALRE or PISSLRE; and host cells that comprise such recombinant expression vectors are disclosed. Oligonucleotide molecules that consist of a nucleotide sequence complimentary to a portion of the nucleotide sequence that encodes PITALRE or PISSLRE are disclosed. Antibodies which bind to epitopes on PITALRE or PISSLRE are disclosed. Nucleic acid molecules that comprise a nucleotide sequence that encodes phosphorylation deficient PITALRE, or a phosphorylation deficient PI SSLRE; recombinant vectors and pharmaceutical compositions that comprise such nucleotide sequences are also disclosed. Methods of identifying compounds which inhibit PITALRE activity are disclosed.Type: GrantFiled: May 16, 2000Date of Patent: November 23, 2004Assignee: Thomas Jefferson UniversityInventor: Antonio Giordano
-
Publication number: 20040229260Abstract: There are provided polypeptides which bind to caspase-8. Production and use of such polypeptides is also provided, as well as DNA encoding them, and vectors and host cells having such DNA.Type: ApplicationFiled: April 1, 2004Publication date: November 18, 2004Applicant: Yeda Research and Development Company LtdInventors: David Wallach, Marcus Schuchmann, Tanya Goncharov
-
Publication number: 20040229308Abstract: The invention provides isolated nucleic acid and amino acid sequences of HsKip3, antibodies to HsKip3, methods of screening for HsKip3a modulators using biologically active HsKip3, and kits for screening for HsKip3a modulators.Type: ApplicationFiled: November 25, 2003Publication date: November 18, 2004Applicant: Cytokinetics, Inc.Inventors: Christophe Beraud, Andrew Craven, Ming Yu, Roman Sakowicz, Umesh A. Patel, Katherine A. Davies
-
Publication number: 20040225117Abstract: The present invention provides amino acid sequences of polypeptides that are encoded by genes within the human genome, the Ras-like protein polypeptides of the present invention. The present invention specifically provides isolated polypeptide and nucleic acid molecules, methods of identifying modulators of the Ras-like protein polypeptides.Type: ApplicationFiled: May 3, 2004Publication date: November 11, 2004Inventors: Gennady V. Merkulov, Fangcheng Gong, Valentina Di Francesco, Ellen M. Beasley
-
Publication number: 20040224385Abstract: Polypeptides that contain zinc finger-nucleotide binding regions that bind to nucleotide sequences of the formula CNN are provided. Compositions containing a plurality of polypeptides, polynucleotides that encode such polypeptides and methods of regulating gene expression with such polypeptides, compositions and polynucleotides are also provided.Type: ApplicationFiled: June 18, 2004Publication date: November 11, 2004Inventors: Carlos F Barbas, Birgit Dreier
-
Patent number: 6815534Abstract: The present invention relates to a novel t-PALP protein which is a member of the serine protease family. In particular, isolated nucleic acid molecules are provided encoding the human t-PALP protein. t-PALP polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of t-PALP activity. Also provided are diagnostic methods for detecting circulatory system-related disorders and therapeutic methods for treating circulatory system-related disorders.Type: GrantFiled: January 29, 2002Date of Patent: November 9, 2004Assignee: Human Genome Sciences, Inc.Inventors: Paul A. Moore, Steven M. Ruben, Reinhard Ebner
-
Publication number: 20040219636Abstract: The object of the present invention is to provide Koji mold aminopeptidases capable of efficiently hydrolyzing persistent peptides and also genes encoding the aminopeptidases. The present invention provides Aspergillus nidulans aminopeptidase and nucleic acid molecules encoding it. In particular, the present invention provides a protein having an amino acid sequence represented by amino acid Nos. 1 to 519 in SEQ ID NO: 2, or a protein containing the substitution, deletion, insertion, addition or inversion of one or more amino acids in said sequence, and which protein has an activity of catalyzing the reaction for releasing an amino acid at an N-terminal of a peptide, and nucleic acid molecules encoding them.Type: ApplicationFiled: September 22, 2003Publication date: November 4, 2004Applicant: AJINOMOTO CO., INC.Inventors: Kyoko Koibuchi, Daiki Ninomiya, Mari Kojima, Yoichi Ueda, Jun-ichi Maruyama, Katsuhiko Kitamoto
-
Publication number: 20040219554Abstract: The present invention relates to a novel target for use in pharmaceutical assays and, more particularly, to an isolated nucleic acid molecule encoding the human DNA binding protein DUE-B, antibodies or antibody derivatives that react with DUE-B, the preparation of cloned and purified DUE-B from bacterial and eukaryotic cells, and the preparation of modified forms of DUE-B fused or not to other polypeptides.Type: ApplicationFiled: February 26, 2004Publication date: November 4, 2004Inventors: Michael Leffak, John Casper
-
Publication number: 20040219667Abstract: The present invention provides a monoclonal antibody which can specifically and efficiently recognize hTERT protein; which is the catalytic subunit of telomerase, and provides a human chimeric antibody, a CDR grafted antibody, a single chain antibody, and a disulfide stabilized antibody each containing the monoclonal antibody. In addition, the present invention provides a method for detecting/quantitating hTERT protein using these antibodies, and provides diagnosis method, diagnosis agent, and therapeutic agent, for diseases, such as cancer, in which telomerase is involved using these antibodies.Type: ApplicationFiled: July 22, 2003Publication date: November 4, 2004Applicant: KYOWA Hakko Kogya Co., Ltd.Inventors: Nobuo Hanai, Motoo Yamasaki, Kenji Shibata, Akiko Furuya, Osamu Mikuni, Hideharu Anazawa
-
Publication number: 20040214247Abstract: Means and method for at least partial inhibition of tumor growth are provided. Methods makes use of binding molecules capable of specifically binding to an epitope present on a subset of fibronectin proteins. By providing an individual with a binding molecule of the invention it is possible to interfere with sites of angiogenesis or sites that seen active angiogenesis in the recent past. Through this interference blood flow is at least in part inhibited. Through this inhibition it is possible to at least in part inhibit processes dependent on active angiogenesis in said individual, such as tumor growth.Type: ApplicationFiled: April 23, 2004Publication date: October 28, 2004Inventors: Cornelis Adriaan De Kruif, Ton Logtenberg, Marinus Theodorus Thomas Pennings, Henriette Christine De Boer
-
Publication number: 20040214212Abstract: A novel gene 254P1D6B and its encoded protein, and variants thereof, are described wherein 254P1D6B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 254P1D6B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 254P1D6B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 254P1D6B can be used in active or passive immunization.Type: ApplicationFiled: January 23, 2004Publication date: October 28, 2004Inventors: Arthur B. Raitano, Aya Jakobovits, Pia M. Challita-Eid, Wangmao Ge, Juan J. Perez-Villar, Steven B. Kanner
-
Publication number: 20040213789Abstract: Specific anti-heparanase antibodies which bind specifically to heparanase having sequence homology to human heparanase, which can be used to treat and diagnose conditions associated with heparanase catalytic activity, for purification of heparanase, and for drug development in heparanase associated conditions are disclosed.Type: ApplicationFiled: August 22, 2003Publication date: October 28, 2004Inventors: Oron Yacoby-Zeevi, Tuvia Peretz, Daphna Miron, Yinon Shlomi, Iris Pecker, Maty Ayal-Hershkovitz, Elena Feinstein, Joel M. Van Gelder, Israel Vlodavsky, Yael Friedmann
-
Publication number: 20040213790Abstract: A human VEGF-related protein (VRP) has been identified and isolated that binds to, and stimulates the phosphorylation of, the receptor tyrosine kinase Flt4. The VRP is postulated to be a third member of the VEGF protein family. Also provided are antibodies that bind to VRP and neutralize a biological activity of VRP, compositions containing the VRP or antibody, methods of use, chimeric polypeptides, and a signal polypeptide for VRP.Type: ApplicationFiled: June 2, 2004Publication date: October 28, 2004Applicant: Genentech, Inc.Inventors: James Lee, William Wood
-
Publication number: 20040213788Abstract: Chimeric, humanized and other RANK-L mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.Type: ApplicationFiled: November 12, 2003Publication date: October 28, 2004Inventors: Raymond W. Sweet, Mark A. Tornetta, Trevor A. Wattam
-
Publication number: 20040209325Abstract: The present invention relates to the mitogen-activated protein kinase called MAPK5. The rice MAPK5 gene, its protein and kinase activity were induced by abscisic acid, pathogen infection, wounding, drought, salt and cold temperature. However, suppression of MAPK5 expression and kinase activity in dsRNAi transgenic plants resulted in constitutive expression of pathogenesis-related genes such as PR-1 and PR-10 but enhanced resistance to fungal and bacterial pathogens. In contrast, overexpressed transgenic lines exhibited elevated MAPK5 kinase activity and increased tolerance to drought, salt and cold stresses. This invention provides methods for increasing tolerance to abiotic and biotic stress in plant using MAPK5.Type: ApplicationFiled: January 31, 2004Publication date: October 21, 2004Inventors: Yinong Yang, Lizhong Xiong
-
Publication number: 20040208881Abstract: Antibodies directed against laiminin B1k are provided.Type: ApplicationFiled: May 7, 2004Publication date: October 21, 2004Applicants: The General Hospital Corporation, a Massachusetts corporation, The State Board of Higher Education on behalf of Oregon Health Sciences UniversityInventors: Robert E. Burgeson, David Wolfe Wagman
-
Publication number: 20040208877Abstract: The present invention provides antibodies or fragments thereof that bind to cancer cells and are important in physiological phenomena, such as cell rolling and metastasis. Therapeutic and diagnostic, prognostic or staging methods and compositions using such antibodies or fragments thereof are also provided. The methods and compositions according to the present invention can be used in diagnosis of and therapy for such diseases as cancer, including tumor growth and metastasis, leukemia, auto-immune disease, and inflammatory disease.Type: ApplicationFiled: June 30, 2003Publication date: October 21, 2004Inventors: Avigdor Levanon, Rachel Ben-Levy, Daniel Plaksin, Esther Szanton, Yocheved Hagai, Hagit Hoch Mar-Chaim
-
Publication number: 20040204576Abstract: The present invention provides novel polynucleotides encoding a human phosphatase polypeptide, BMY_HPP13, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptide. The invention further relates to diagnostic and therapeutic methods for applying this novel human phosphatase polypeptide to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.Type: ApplicationFiled: July 2, 2003Publication date: October 14, 2004Inventors: Donald Jackson, Gary L. Schieven, Stanley R. Krystek, John N. Feder, Thomas C. Nelson, Donna A. Bassolino